These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29788240)

  • 21. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
    Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
    Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
    Martin A; Nachury M; Peyrin-Biroulet L; Bouhnik Y; Nancey S; Bourrier A; Serrero M; Fumery M; Buisson A; Laharie D; Gilletta C; Filippi J; Allez M; Bouguen G; Roblin X; Altwegg R; Dib N; Pineton de Chambrun G; Savoye G; Carbonnel F; Viennot S; Amiot A;
    J Crohns Colitis; 2020 Jul; 14(7):896-903. PubMed ID: 31930285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients.
    Cicala M; Gori M; Balestrieri P; Altomare A; Tullio A; Di Cola S; Dejongh S; Graziani MG; Pagnini C; Carotti S; Perrone G; Ribolsi M; Fiorani M; Guarino MPL; Farré R
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 27. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
    Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
    Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
    Macaluso FS; Ventimiglia M; Fries W; Viola A; Cappello M; Scrivo B; Magnano A; Pluchino D; Camilleri S; Garufi S; Mitri RD; Mocciaro F; Magrì G; Ferracane C; Citrano M; Graziano F; Bertolami C; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    Dig Liver Dis; 2020 Dec; 52(12):1461-1466. PubMed ID: 32601033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
    Shelton E; Allegretti JR; Stevens B; Lucci M; Khalili H; Nguyen DD; Sauk J; Giallourakis C; Garber J; Hamilton MJ; Tomczak M; Makrauer F; Burakoff RB; Levine J; de Silva P; Friedman S; Ananthakrishnan A; Korzenik JR; Yajnik V
    Inflamm Bowel Dis; 2015 Dec; 21(12):2879-85. PubMed ID: 26288002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
    Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
    Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
    Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
    J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
    J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
    Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
    Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
    United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
    Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Medici A; Forti G; Franceschi M; Ferronato A; Gallina S; Grasso G; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino' S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Scorza S; Zampaletta C; Picchio M; Elisei W
    Eur J Intern Med; 2019 Aug; 66():85-91. PubMed ID: 31208827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
    Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.